8-K: Processa Pharmaceuticals Announces At-the-Market Offering of up to $2.4 Million in Common Stock

Processa Pharmaceuticals has entered into a sales agreement to potentially sell up to $2.4 million of its common stock through an at-the-market offering.

Summary

• Processa Pharmaceuticals has entered into a sales agreement with A.G.P./Alliance Global Partners to sell shares of its common stock through an at-the-market (ATM) offering.
• The company may sell up to $2.4 million worth of shares.
• The net proceeds from the offering are intended for research and development, particularly for oncology products, as well as for working capital and general corporate purposes.
• The sales will be made at prevailing market prices, and the sales agent will receive up to 3.0% of the gross proceeds.
• Processa is not obligated to sell any shares, and there is no guarantee of the price or amount of shares that will be sold.
• The sales agreement will terminate when all shares are sold or the agreement is terminated.
• The offering is contingent upon the effectiveness of the company's registration statement on Form S-3 filed on May 21, 2024.

Sentiment

Score: 6

Explanation: The announcement is neutral to slightly positive. It provides a means for the company to raise capital, but also introduces potential dilution for existing shareholders. The terms are standard for this type of offering.

Positives

• The at-the-market offering provides a flexible way for Processa to raise capital.
• The funds raised will support the company's research and development efforts, particularly in oncology.
• The agreement allows the company to sell shares at prevailing market prices.

Negatives

• The company is not obligated to sell any shares, so the full $2.4 million may not be raised.
• There is no guarantee of the price or amount of shares that will be sold.
• The sales agent will receive a commission of up to 3.0% of the gross proceeds, which will reduce the net proceeds to the company.

Risks

• The company may not be able to sell all of the shares offered.
• The price of the shares may fluctuate, impacting the amount of capital raised.
• The offering is contingent upon the effectiveness of the company's registration statement on Form S-3.
• There is no guarantee that the company will be able to raise the full $2.4 million.

Future Outlook

The company intends to use the net proceeds from the offering for continued research and development of its drug candidates, especially oncology products, and for working capital and general corporate purposes. The company may sell some or all of the shares, but is not obligated to do so.

Management Comments

• The company expects to use net proceeds from the ATM Offering over time for continued research and development for our portfolio of drug candidates, especially our oncology products, and working capital and general corporate purposes.

Industry Context

At-the-market offerings are a common method for biotech companies to raise capital, especially when they need to fund ongoing research and development. This allows them to access capital without the need for a large, dilutive secondary offering.

Comparison to Industry Standards

• Many small-cap biotech companies use at-the-market offerings to raise capital, as it provides flexibility and avoids large discounts associated with traditional secondary offerings.
• The 3% commission to the sales agent is within the typical range for such offerings.
• Comparable companies such as XOMA Corporation and Celldex Therapeutics have used similar ATM offerings to fund their operations and research.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• The company's ability to fund research and development may improve, potentially benefiting long-term shareholders.
• The company's financial stability may improve with the additional capital.

Next Steps

• The company will proceed with the at-the-market offering once the registration statement on Form S-3 is effective.
• The company will sell shares through the sales agent at prevailing market prices.
• The company will use the net proceeds for research and development, working capital, and general corporate purposes.

Key Dates

Keywords

at-the-market offering, common stock, capital raise, oncology, research and development, sales agreement, Processa Pharmaceuticals, A.G.P./Alliance Global Partners